Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure - ATOMIC-AHF


Omecamtiv mecarbil is a novel cardiac-specific myosin activator. The current study was a phase II study designed to evaluate the effect of 48 hours of intravenous (IV) omecamtiv mecarbil compared with placebo on dyspnea in subjects with left ventricular (LV) systolic dysfunction hospitalized for acute heart failure (HF).